BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $IDYA readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05987332-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:IDE196 readout (P2/3) · IDEAYA Biosciences $IDYA
DESCRIPTION:IDE196 (Darovasertib) in Combination With Crizotinib as First-l
 ine Therapy in Metastatic Uveal Melanoma\n\nPrimary completion date: 2027-
 01-15 (estimated)\nPhase 2/3 · Oncology · Metastatic Uveal Melanoma\nEnr
 ollment: 420 · Sites: 68\n\nPrimary completion = last participant's prima
 ry-endpoint data collected\; topline results usually follow weeks to month
 s later. Sponsor-reported\, often an estimate. Not investment advice.\n\nh
 ttps://datacutoff.com/radar.html?nct=NCT05987332\nhttps://clinicaltrials.g
 ov/study/NCT05987332
URL:https://datacutoff.com/radar.html?nct=NCT05987332
CATEGORIES:Oncology,Phase 2/3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05907954-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Darovasertib readout (P2) · IDEAYA Biosciences $IDYA
DESCRIPTION:(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized 
 Ocular Melanoma\n\nPrimary completion date: 2027-04-30 (estimated)\nOrigin
 ally planned: 2026-01-31 (+14.9 months)\nPhase 2 · Oncology · Uveal Mela
 noma\nEnrollment: 160 · Sites: 18\n\nPrimary completion = last participan
 t's primary-endpoint data collected\; topline results usually follow weeks
  to months later. Sponsor-reported\, often an estimate. Not investment adv
 ice.\n\nhttps://datacutoff.com/radar.html?nct=NCT05907954\nhttps://clinica
 ltrials.gov/study/NCT05907954
URL:https://datacutoff.com/radar.html?nct=NCT05907954
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
